
Home » Hair transplant » Olumiant for Alopecia Areata
Alopecia areata is a common autoimmune disorder that results in hair loss. It is estimated to affect about 6.8 million people in the United States and 147 million people worldwide. The condition is characterized by hair falling out in small, round patches, usually about the size of a quarter. However, in some cases, the hair loss can be more widespread, affecting larger areas of the scalp.
When there is a complete loss of hair on the scalp, it is referred to as alopecia totalis. If hair loss occurs throughout the entire body, including the scalp, eyebrows, eyelashes, beard, and body hair, it is called alopecia universalis. In some cases, the hair loss can be temporary, with hair regrowth occurring within a few months. However, in other cases, the hair loss can be permanent.
Alopecia areata can affect anyone, regardless of age, gender, or race. The condition is more common in people under the age of 30, but it can occur at any age. The exact cause of alopecia areata is not known, but it is believed to be an autoimmune disorder in which the body’s immune system mistakenly attacks hair follicles, causing them to stop producing hair.
Symptoms of alopecia areata include the sudden appearance of small, round patches of hair loss, itching or burning sensations on the scalp, and increased hair fragility or breakage. A dermatologist can usually diagnose alopecia areata by examining the scalp, but a biopsy may be needed to confirm the diagnosis.
Alopecia areata is an autoimmune disorder that results in hair loss. The exact cause of the condition is not fully understood, but it is believed to occur when the body’s immune system mistakenly attacks the cells in hair follicles. This causes the hair follicles to shrink and dramatically slows down hair production, resulting in hair loss. The hair loss can occur in small, round patches, usually about the size of a quarter, but in some cases, it can be more widespread, affecting larger areas of the scalp.
One of the key factors in the development of alopecia areata is genetics. Studies have shown that people with a family history of the disease are more likely to develop the condition. In fact, one in five people with alopecia areata has a family member who has also developed the disorder. This suggests that there may be a genetic component to the disease. Additionally, research has found that many people with a family history of alopecia areata also have a personal or family history of other autoimmune disorders, such as atopy, thyroiditis, and vitiligo.
Despite the strong genetic component, the exact genetic mechanisms behind the development of alopecia areata are not fully understood. Scientists are still working to identify the specific genes and genetic variations that increase the risk of developing the condition.
It’s important to note that stress is not considered to be a major cause of alopecia areata, despite some people believing that stress can trigger the condition. While extreme cases of stress can potentially trigger the condition, most recent research points towards a genetic cause. However, stress can exacerbate symptoms of alopecia areata and it’s important to manage stress levels in order to maintain healthy hair growth.
Treatment options for alopecia areata include corticosteroid injections, topical minoxidil, and topical or oral immunomodulatory drugs. In some cases, hair regrowth can be achieved with the use of these treatments. However, there is currently no cure for alopecia areata and treatment is often focused on managing symptoms and promoting hair regrowth.
Olumiant is a prescription medication that has been approved by the FDA for the treatment of moderate to severe active rheumatoid arthritis in adults when other drugs, such as TNF blockers, have not been effective. It is also approved for the treatment of severe alopecia areata in adults and for in-hospital treatment of severe COVID-19 in adults when oxygen therapy, ventilation, or ECMO treatment is needed to assist with breathing.
The active ingredient in Olumiant is baricitinib, which belongs to a class of drugs known as Janus kinase inhibitors. These drugs help to reduce inflammation by decreasing the activity of the immune system. Olumiant is taken as a tablet once a day and is available in three strengths: 1 mg, 2 mg, and 4 mg.
When taking Olumiant, it is important to follow your doctor’s instructions carefully. The dosage may be adjusted by your doctor as needed.
If you have difficulty swallowing tablets, it is important to speak with your doctor as alternative methods of administration may be available. Before starting treatment with Olumiant, your doctor may perform tests to ensure you do not have any other infections such as tuberculosis.
It is important to note that while taking Olumiant, you may be more susceptible to infections, and regular medical tests will be required. If you have a history of shingles, it is important to note that Olumiant may cause the virus to become active or worsen.
For COVID-19 treatment, it is important to remain under the care of a doctor for the full prescribed length of treatment, usually for 14 days or until you are discharged from the hospital.
When it comes to storage, Olumiant should be kept at room temperature, away from moisture and heat. It is important to store the medication as directed to maintain its effectiveness.
It is important to seek immediate medical attention if you experience symptoms such as a fever, night sweats, constant tiredness, weight loss, stomach pain, diarrhea or changes in bowel habits, trouble breathing, wheezing, a severe cough, or lumps in your neck, armpits, or groin.
Additionally, if you experience sudden shortness of breath, chest pain spreading to your neck or arms, nausea, severe dizziness, a cold sweat, weakness on one side of your body, slurred speech, or pain, redness, or swelling in an arm or leg, seek emergency medical help.
Individuals should not start taking Olumiant if they have any kind of infection. Your doctor may perform tests to make sure you do not have tuberculosis or other infections before starting the treatment.